Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026156 · ClinicalTrials.gov registry record · Phase 2
S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00026156 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 125 participants.
The verdict
NCT00026156, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients who have advanced non-small cell lung cancer.
Interventions
- DRUG docetaxel
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026156
The ClinicalTrials.gov registry entry for NCT00026156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00026156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026156 about?
NCT00026156 is a clinical study titled "S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine followed by docetaxel in treating patients who have advanced non-small cell lung cancer.
What is the current status of trial NCT00026156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2001-11. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00026156?
The interventions under investigation include: docetaxel (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00026156?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.